NCT03306927

Brief Summary

This study is part of a group of studies whose overall goal is to accurately define the physiochemical and structural effects of pea varieties and relate these to blood glucose attenuation and appetite related sensations in healthy human volunteers.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 2, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 11, 2017

Completed
28 days until next milestone

Study Start

First participant enrolled

November 8, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 12, 2019

Completed
5.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

November 29, 2024

Status Verified

November 1, 2024

Enrollment Period

2 years

First QC Date

October 2, 2017

Last Update Submit

November 26, 2024

Conditions

Keywords

blood sugarinsulinappetitepeas

Outcome Measures

Primary Outcomes (2)

  • Post-prandial glucose

    iAUC for glucose

    120 min

  • Post-prandial insulin

    iAUC insulin

    120 min

Secondary Outcomes (1)

  • Appetite scores

    120 min

Other Outcomes (4)

  • Calorie consumption

    16 h

  • Metabolomics

    120 min

  • Acceptability of test products

    15 min

  • +1 more other outcomes

Study Arms (4)

Whole yellow pea

EXPERIMENTAL

Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili

Dietary Supplement: Whole yellow pea chili

Split yellow pea

EXPERIMENTAL

Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili

Dietary Supplement: Split yellow pea chili

Rice-PPGR

PLACEBO COMPARATOR

Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili

Dietary Supplement: Rice chili

Rice-Satiety

PLACEBO COMPARATOR

Rice chili with the same calories as the pea chili. Intervention: Rice chili

Dietary Supplement: Rice chili

Interventions

Whole yellow pea chiliDIETARY_SUPPLEMENT

Chili containing whole yellow peas

Whole yellow pea
Split yellow pea chiliDIETARY_SUPPLEMENT

Chili containing split yellow peas

Split yellow pea
Rice chiliDIETARY_SUPPLEMENT

Chili containing long grain white rice

Rice-PPGRRice-Satiety

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Generally healthy male or female, between the age of 18-40 years;
  • Body mass index (BMI) 18.5-30.0 kg/m2;
  • Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening, respectively.
  • Willing to provide informed consent;
  • Willing/able to comply with the requirements of the study.

You may not qualify if:

  • Pregnant or lactating;
  • Medical history of diabetes mellitus, fasting blood glucose ≥6.1 mmol/L, HbA1c ≥6.0%, or use of insulin or oral medication to control blood sugar;
  • Medical history of cardiovascular disease;
  • Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg;
  • Fasting plasma total cholesterol \>7.8 mmol/L;
  • Fasting plasma HDL \<0.9 mmol/L;
  • Fasting plasma LDL \>5.0 mmol/L;
  • Fasting plasma triglycerides \>2.3 mmol/L;
  • Major surgery within the last 3 months;
  • Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;
  • Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥1.5 times the upper limit of normal (ULN));
  • Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥ 1.8 times the ULN));
  • Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
  • Active treatment for any type of cancer within 1 year prior to study start;
  • Shift worker (a system of employment where an individual's normal hours of work are in part, outside the period of normal working day; 6am and 8pm);
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

I.H. Asper Clinical Research Institute

Winnipeg, Manitoba, R2H2A6, Canada

Location

Related Publications (17)

  • Public Health Agency of Canada and the Canadian Institute for Health Information. Obesity in Canada: A joint report from the Public Health Agency of Canada and the Canadian institute for health information. Government of Canada; 2011.

    BACKGROUND
  • Public Health Authority of Canada. Diabetes in Canada: Facts and figures from a public health perspective. 2011.

    BACKGROUND
  • Sievenpiper JL, Kendall CW, Esfahani A, Wong JM, Carleton AJ, Jiang HY, Bazinet RP, Vidgen E, Jenkins DJ. Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes. Diabetologia. 2009 Aug;52(8):1479-95. doi: 10.1007/s00125-009-1395-7. Epub 2009 Jun 13.

    PMID: 19526214BACKGROUND
  • Hamberg O, Rumessen JJ, Gudmand-Hoyer E. Blood glucose response to pea fiber: comparisons with sugar beet fiber and wheat bran. Am J Clin Nutr. 1989 Aug;50(2):324-8. doi: 10.1093/ajcn/50.2.324.

    PMID: 2547300BACKGROUND
  • Marinangeli CP, Jones PJ. Chronic intake of fractionated yellow pea flour reduces postprandial energy expenditure and carbohydrate oxidation. J Med Food. 2011 Dec;14(12):1654-62. doi: 10.1089/jmf.2010.0255.

    PMID: 22145774BACKGROUND
  • Smith CE, Mollard RC, Luhovyy BL, Anderson GH. The effect of yellow pea protein and fibre on short-term food intake, subjective appetite and glycaemic response in healthy young men. Br J Nutr. 2012 Aug;108 Suppl 1:S74-80. doi: 10.1017/S0007114512000700.

    PMID: 22916818BACKGROUND
  • Jenkins DJ, Thorne MJ, Camelon K, Jenkins A, Rao AV, Taylor RH, Thompson LU, Kalmusky J, Reichert R, Francis T. Effect of processing on digestibility and the blood glucose response: a study of lentils. Am J Clin Nutr. 1982 Dec;36(6):1093-101. doi: 10.1093/ajcn/36.6.1093.

    PMID: 6293296BACKGROUND
  • Li H, Song F, Xing J, Tsao R, Liu Z, Liu S. Screening and structural characterization of alpha-glucosidase inhibitors from hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MS(n) and SORI-CID FTICR MS. J Am Soc Mass Spectrom. 2009 Aug;20(8):1496-503. doi: 10.1016/j.jasms.2009.04.003. Epub 2009 Apr 14.

    PMID: 19443236BACKGROUND
  • Habtemariam S. A-glucosidase inhibitory activity of kaempferol-3-O-rutinoside. Nat Prod Commun. 2011 Feb;6(2):201-3.

    PMID: 21425674BACKGROUND
  • Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, Westerterp M. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010 Mar;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x. Epub 2010 Jan 29.

    PMID: 20122136BACKGROUND
  • European Food Safety Authority. Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal. 2012;10(3):2604.

    BACKGROUND
  • Health Canada. Draft guidance document: Satiety health claims on food [Internet].; 2012. Available from: http://www.hc-sc.gc.ca/fn-an/consult/satiety-satiete/document-consultation-eng.php.

    BACKGROUND
  • Ames N, Blewett H, Storsley J, Thandapilly SJ, Zahradka P, Taylor C. A double-blind randomised controlled trial testing the effect of a barley product containing varying amounts and types of fibre on the postprandial glucose response of healthy volunteers. Br J Nutr. 2015 May 14;113(9):1373-83. doi: 10.1017/S0007114515000367. Epub 2015 Apr 8.

    PMID: 25850814BACKGROUND
  • Johansson G, Westerterp KR. Assessment of the physical activity level with two questions: validation with doubly labeled water. Int J Obes (Lond). 2008 Jun;32(6):1031-3. doi: 10.1038/ijo.2008.42. Epub 2008 Apr 8.

    PMID: 18392036BACKGROUND
  • Rabiee A, Magruder JT, Grant C, Salas-Carrillo R, Gillette A, DuBois J, Shannon RP, Andersen DK, Elahi D. Accuracy and reliability of the Nova StatStrip(R) glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010 Sep 1;4(5):1195-201. doi: 10.1177/193229681000400519.

    PMID: 20920440BACKGROUND
  • Mollard RC, Luhovyy BL, Smith C, Anderson GH. Acute effects of pea protein and hull fibre alone and combined on blood glucose, appetite, and food intake in healthy young men--a randomized crossover trial. Appl Physiol Nutr Metab. 2014 Dec;39(12):1360-5. doi: 10.1139/apnm-2014-0170. Epub 2014 Aug 2.

    PMID: 25302637BACKGROUND
  • Akhavan T, Anderson GH. Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men. Am J Clin Nutr. 2007 Nov;86(5):1354-63. doi: 10.1093/ajcn/86.5.1354.

    PMID: 17991646BACKGROUND

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Heather Blewett, PhD

    Agriculture and Agri-Food Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Randomized, controlled, cross-over study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 2, 2017

First Posted

October 11, 2017

Study Start

November 8, 2017

Primary Completion

November 12, 2019

Study Completion

January 1, 2025

Last Updated

November 29, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will share

All IPD that underlie results in a publication.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
From the time the data is collected until manuscript is accepted for publication.
Access Criteria
Dan Ramdath, Sora Ludwig and Michel Aliani will have access to data necessary for manuscript preparation.

Locations